ArticleDementia and geriatric cognitive disorders2026
Prognostic Value of CSF Total Tau Protein in Patients with Familial and Sporadic Creutzfeldt-Jakob Disease.
Article in Dementia and geriatric cognitive disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionElevated total tau protein (t-τ) in the cerebrospinal fluid (CSF) is routinely used as a marker of Creutzfeldt-Jakob disease (CJD). We hypothesized that CSF t-τ and patients' age may anticipate survival time (ST) also in subjects with familial CJD (f-CJD) as has been shown previously in sporadic CJD (s-CJD).
methodsWe analyzed data from the Israeli National CJD Registry from 1991 to 2022. The data included cases of both f-CJD and s-CJD in whom demographic data and CSF t-τ levels were measured, and the date of death was available. Using X-tile software, we determined the optimal cut-off points for continuous variables in survival analysis and found the cut-points for t-τ level and patients' age.
resultsWe analyzed data on 183 sequential CJD patients. The data included definite (n = 9), probable (n = 165), and possible (n = 9) CJD cases of whom 120 (61 males) were f-CJD (65.6%) and 63 (35 males) patients were s-CJD (34.4%). The cut-off value of CSF t-τ level was found to be 1,226 pg/mL. It separated ST into two groups, 105 days (interquartile ranges [IQR]: 59-305) in the lower group vs. 59 days (IQR: 29.5-147.5) in the higher, p = 0.0005. Cox analyses showed that for every 100 pg/mL increase in CSF t-τ, ST shortened by 3% in days (Exp β = 1.0003; 95% confidence interval: 1.0001-1.0005). Age had no direct prognostic value but correlated with CSF t-τ levels (rho = 0.243, p < 0.001).
conclusionsAge and CSF t-τ levels above the cut-off value predict ST shortening in patients with both f-CJD and s-CJD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.